Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - CV Therapeutics, Inc. (NasdaqNM:CVTX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
3172 Porter Drive
Palo Alto, CA 94304
Phone: (650) 812-0585
Fax: (650) 858-0390
Email: investor_relations@cvt.com
Employees (last reported count): 134
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 51%
·Over the last 6 months:
 · one insider buy; 2,000  shares
 · 3 insider sells; 18.0K shares
  (0.2% of insider shares)
·Institutional: 83% (168% of float)
(229 institutions)
·Net Inst. Buying: 2.35M shares (+11.34%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
CV Therapeutics, Inc is a biopharmaceutical company engaged in the discovery and development of new small-molecule drugs to treat cardiovascular disease. The Company is conducting clinical trials for three of its drug candidates. Ranolazine, the first in a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors, is in Phase III clinical trials for the potential treatment of chronic angina. CVT-510, an A1 adenosine receptor agonist, is in Phase II clinical trials for the potential treatment of atrial arrhythmias. CVT-3146, an A2A adenosine receptor agonist, is in Phase I clinical trials for the potential use as an adjunctive pharmacologic agent in cardiac perfusion imaging studies.
More from Market Guide: Expanded Business Description

Financial Summary
CV Therapeutics is a biopharmaceutical company engaged in the discovery and development of new small molecule drugs to treat cardiovascular diseases. For the six months ended 6/30/01, revenues rose 42% to $2.8 million. Net loss totaled $34.5 million, up from $14.5 million. Revenues reflect the milestone payment from Biogen, Inc. Higher loss reflects greater external costs associated with the Company's clinical programs and increased personnel expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Louis Lange, M.D., Ph.D., 52
Chairman and CEO
$548K$1.8M
Daniel Spiegelman, 42
CFO, Sr. VP
318K2.5M
Andrew Wolff, M.D., 46
Sr. VP, Clinical R&D
330K1.6M
Tricia Suvari, J.D., 40
VP, Gen. Counsel, Assistant Sec.
--  --  
David McCaleb, 48
VP of Marketing
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CVTXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 23-Mar-2001
$21.078
Recent Price$49.77 
52-Week High
on 7-Nov-2000
$93.125
Beta0.18 
Daily Volume (3-month avg)394.9K
Daily Volume (10-day avg)311.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-32.1%
52-Week Change
relative to S&P500
-8.8%
Share-Related Items
Market Capitalization$1.11B
Shares Outstanding22.2M
Float10.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$7.38 
Earnings (ttm)-$2.98 
Earnings (mrq)-$0.96 
Sales (ttm)$0.21 
Cash (mrq)$16.57 
Valuation Ratios
Price/Book (mrq)6.75 
Price/EarningsN/A 
Price/Sales (ttm)233.94 
Income Statements
Sales (ttm)$4.14M
EBITDA (ttm)-$64.9M
Income available to common (ttm)-$58.4M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-18.60%
Return on Equity (ttm)-60.72%
Financial Strength
Current Ratio (mrq)20.61 
Debt/Equity (mrq)1.23 
Total Cash (mrq)$362.1M
Short Interest
As of 8-Aug-2001
Shares Short2.16M
Percent of Float19.8%
Shares Short
(Prior Month)
1.99M
Short Ratio5.76 
Daily Volume375.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.